<DOC>
	<DOCNO>NCT00914849</DOCNO>
	<brief_summary>To reduce number donor treat IV AMD3100 require second collection obtain minimum cell necessary allogeneic stem cell transplant .</brief_summary>
	<brief_title>Intravenous ( IV ) AMD3100 Mobilization Matched Related Transplant Advanced Hematological Malignancies</brief_title>
	<detailed_description>- To reduce number donor treat intravenous ( IV ) AMD3100 require second collection obtain minimum CD34/kg ( 2 X 106 ) necessary allogeneic stem cell transplantation compare historic group receive 240ug SC AMD3100 33 % ( 8 24 ) 11 % ( 3 27 ) . - To estimate 95 % confidence interval proportion human leukocyte antigen ( HLA ) -identical sibling donor experience grade 3-4 infusional toxicity proportion ≥ 2.0 x 10e6 CD34+ cells/kg recipient weight safely mobilize follow one two intravenous infusion . - To determine kinetics stem cell lymphocyte mobilization use IV AMD3100 determine peripheral blood stem cell product collect mobilization IV AMD3100 use safely hematopoietic cell transplantation HLA-matched recipient measure neutrophil engraftment day +21 . - To determine pharmacokinetics pharmacodynamics IV AMD3100 stem cell T-cell phenotyping immune reconstitution transplantation . - To determine rate acute graft-versus-host disease ( GVHD ) chronic GVHD patient receive IV AMD3100 mobilize peripheral blood stem cell .</detailed_description>
	<mesh_term>Hematologic Neoplasms</mesh_term>
	<mesh_term>JM 3100</mesh_term>
	<criteria>Donor Eligibility Donor 18 70 year age inclusive . If female childbearing age : must nonpregnant , breast feeding agree use adequate contraception . Donor 6/6 HLAmatched sibling willing donate PBSC transplant . Donor must willing provide write informed consent . Adequate cardiac function history congestive heart failure history atrial fibrillation ventricular tachyarrhythmia . Adequate renal function define calculated serum creatinine clearance ≥75 % normal ( CockcroftGault equation ) . Adequate hepatic function define total bilirubin &lt; 2x normal absence hepatic fibrosis/cirrhosis . Adequate neurologic function define NO evidence severe central peripheral neurologic abnormality . No history cerebrovascular accident seizure disorder require anticonvulsant medication . Donor must HIV1 &amp; 2 antibody HTLVI &amp; II antibody seronegative , Food Drug Administration ( FDA ) license test . Donor must Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Donor must demonstrate ability compliant study regimen . Donor must active infection time study entry . Donor active alcohol substance abuse within 6 month study entry . Donor currently enrol another investigational agent study . Donor medical condition , , opinion clinical investigator , would interfere his/her evaluation . Recipient Eligibility Recipient must available successful collection AMD3100 mobilize product . When adequate collection obtain use GCSF , recipient may need receive combine product mobilize cell AMD3100 g granulocytecolony stimulate factor ( GCSF ) . Recipients receive less 2.0 X 106 CD34+ cells/kg/actual recipient weight two day IV AMD3100 consider `` eligible '' follow per protocol safety purpose . Patient 18 65 year age inclusive . Patient willing 6/6 HLAmatched sibling willing donate PBSC transplant . Patient must provide sign informed consent . If female childbearing age : must nonpregnant , breast feeding , use adequate contraception . Patient must one follow diagnosis : Acute myelogenous leukemia ( AML ) 1st subsequent remission relapse , Acute lymphoblastic leukemia ( ALL ) 1st subsequent remission relapse , Myelodysplastic syndrome either intermediate 1 2 , high risk International Prognostic Scoring System , Chronic myelogenous leukemia ( CML ) accelerate second chronic phase , NonHodgkin 's lymphoma ( NHL ) Hodgkin 's disease ( HD ) 2nd great complete remission , partial remission , refractory relapse , Chronic lymphocytic leukemia ( CLL ) , Rai Stage 24 , fail least 2 prior regimen , OR Multiple myeloma ( MM ) , Stage 23 . Adequate cardiac function leave ventricular ejection fraction ≥ 40 % . Adequate pulmonary function define NO severe symptomatic restrictive obstructive lung disease , formal pulmonary function test show FEV1 ≥50 % predict DLCO ≥40 % predict , correct hemoglobin . Adequate renal function define serum creatinine clearance ≥75 % normal ( CockcroftGault equation ) . Adequate hepatic function define total bilirubin &lt; 2x normal absence hepatic fibrosis/cirrhosis . Adequate neurologic function define NO evidence severe central peripheral neurologic abnormality . Patients history previous central nervous system ( CNS ) tumor involvement eligible provide without symptom sign CNS free disease lumbar puncture CT scan brain . No evidence active infection time transplant preparative regimen time transplantation . Patient must HIV1 &amp; 2 antibody HTLVI &amp; II antibody seronegative , FDA license test . Patient ECOG performance status 0 1 . Patient must demonstrate ability compliant medical regimen . Patient must active alcohol substance abuse within 6 month study entry . Patient must enrol another investigational agent concurrently . Patient must medical condition , , opinion clinical investigator , would interfere evaluation patient . See Inclusion criterion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>